FENC (Fennec Pharmaceuticals) צמיחת רווח נקי למניה השנה
Geopolitical instability regarding Asian supplies is creating volatility, which the GURU.Markets service reflects in the year-over-year change in EPS. The value of this indicator is 181.60. Risks associated with changes in chemotherapy protocols are mitigated by Pedmark's monopoly and FDA protection, ensuring Fennec Pharmaceuticals (FENC) achieves high returns within the narrow segment of hearing loss therapy.
פילוחי מדדים פיננסיים ומדדי שוק עבור Fennec Pharmaceuticals (FENC)
Investors utilize earnings per share dynamics to evaluate business scaling efficiency and the pace of net income capitalization. This indicator measures the percentage deviation of current EPS from the previous year's value, which, during the commercial expansion of PEDMARK and a lull in R&D at Fennec Pharmaceuticals (FENC), allows analysts to filter out market noise and identify real profitability through the year-over-year EPS trend.
